These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 26072262)

  • 1. Peroxisome proliferator-activated receptor (PPAR) gamma in cardiovascular disorders and cardiovascular surgery.
    Ivanova EA; Parolari A; Myasoedova V; Melnichenko AA; Bobryshev YV; Orekhov AN
    J Cardiol; 2015 Oct; 66(4):271-8. PubMed ID: 26072262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peroxisome Proliferator-Activated Receptor (PPAR) Gamma Agonists as Therapeutic Agents for Cardiovascular Disorders: Focus on Atherosclerosis.
    Ivanova EA; Myasoedova VA; Melnichenko AA; Orekhov AN
    Curr Pharm Des; 2017; 23(7):1119-1124. PubMed ID: 27855608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutical effects of PPAR agonists assessed by biomarker modulation.
    Chinetti-Gbaguidi G; Fruchart JC; Staels B
    Biomarkers; 2005 Nov; 10 Suppl 1():S30-6. PubMed ID: 16298909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effects of PPARgamma agonist on dyslipidemia and atherosclerosis].
    Komatsu A; Node K
    Nihon Rinsho; 2010 Feb; 68(2):294-8. PubMed ID: 20158099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PPAR dual agonists: are they opening Pandora's Box?
    Balakumar P; Rose M; Ganti SS; Krishan P; Singh M
    Pharmacol Res; 2007 Aug; 56(2):91-8. PubMed ID: 17428674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature.
    Duan SZ; Usher MG; Mortensen RM
    Circ Res; 2008 Feb; 102(3):283-94. PubMed ID: 18276926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of peroxisome proliferator-activated receptor-γ in atherosclerosis: an update.
    Wang N; Yin R; Liu Y; Mao G; Xi F
    Circ J; 2011; 75(3):528-35. PubMed ID: 21325726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peroxisome proliferator-activated receptor-gamma and its agonists in hypertension and atherosclerosis : mechanisms and clinical implications.
    Halabi CM; Sigmund CD
    Am J Cardiovasc Drugs; 2005; 5(6):389-98. PubMed ID: 16259527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) as a Target for Concurrent Management of Diabetes and Obesity-Related Cancer.
    Wang Q; Imam MU; Yida Z; Wang F
    Curr Pharm Des; 2017; 23(25):3677-3688. PubMed ID: 28677503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
    Touyz RM; Schiffrin EL
    Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Protective role of PPARgamma agonists against cardiovascular disease].
    Yamagishi S
    Nihon Rinsho; 2010 Feb; 68(2):307-11. PubMed ID: 20158101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator.
    Kurtz TW
    Acta Diabetol; 2005 Apr; 42 Suppl 1():S9-16. PubMed ID: 15868121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists.
    Libby P; Plutzky J
    Am J Cardiol; 2007 Feb; 99(4A):27B-40B. PubMed ID: 17307056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The nuclear hormone receptor PPARγ as a therapeutic target in major diseases.
    Schmidt MV; Brüne B; von Knethen A
    ScientificWorldJournal; 2010 Nov; 10():2181-97. PubMed ID: 21057731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Role of PPARγ, a transcription factor in cardiovascular disease].
    Mukohda M
    Nihon Yakurigaku Zasshi; 2019; 154(2):56-60. PubMed ID: 31406043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus.
    Ríos-Vázquez R; Marzoa-Rivas R; Gil-Ortega I; Kaski JC
    Am J Cardiovasc Drugs; 2006; 6(4):231-42. PubMed ID: 16913824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weight-loss-associated induction of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma correlate with reduced atherosclerosis and improved cardiovascular function in obese insulin-resistant mice.
    Verreth W; De Keyzer D; Pelat M; Verhamme P; Ganame J; Bielicki JK; Mertens A; Quarck R; Benhabilès N; Marguerie G; Mackness B; Mackness M; Ninio E; Herregods MC; Balligand JL; Holvoet P
    Circulation; 2004 Nov; 110(20):3259-69. PubMed ID: 15533870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peroxisome proliferator-activated receptor-gamma in vascular biology.
    Li J; Wang N
    Cardiovasc Hematol Disord Drug Targets; 2007 Jun; 7(2):109-17. PubMed ID: 17584045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peroxisome proliferator-activated receptor gamma and cardiovascular diseases.
    Takano H; Komuro I
    Circ J; 2009 Feb; 73(2):214-20. PubMed ID: 19129679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationships among ET-1, PPARgamma, oxidative stress and endothelial dysfunction in diabetic animals.
    Matsumoto T; Kobayashi T; Kamata K
    J Smooth Muscle Res; 2008 Apr; 44(2):41-55. PubMed ID: 18552452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.